Artistic computer rendering of a molecule.
The William C. Davis
Monoclonal Antibody Center
Panels of monoclonal antibodies are available for a variety of species.

The William C. Davis Monoclonal Antibody Center

It is with great sadness that we share the passing of Dr. Davis. While this is a significant loss for our team and community, we remain committed to honoring his vision by continuing the important work of the service center.

As we navigate this transition, some services and response times may be slower than usual. We appreciate your patience and understanding as we adapt and move forward.

We are grateful for your continued support and look forward to serving you for many years to come.

If you have questions or concerns, please contact us.

The Monoclonal Antibody Center provides a range of services related to the production and characterization of monoclonal antibodies to researchers and clinicians affiliated with WSU. 

Monoclonal antibodies to leukocyte differentiation molecules, activation molecules, and MHC Class I and II molecules in many species of food and companion animals have been produced by the WSU Monoclonal Antibody Center.  All antibodies are developed in mice.

Taxonomic Key Program is a searchable database that allows researchers to easily identify monoclonal antibody-defined molecules by their physical characteristics.


Isotype controls

Catalog #mAbIg isotypeE coli J5
COL2001COLIS69AIgG1E coli J5
COL2002COLIS205CIgG2aE coli J5
COL2003COLIS169AIgG2bE coli J5
COL2004COLIS41BIgG3E coli J5
COL2005COLIS52A2IgME coli J5

Monoclonal antibodies by species

CloneIg IsotypeSpecificityBisonLlama and alpacaCatCattleChickenDogDolphinFerretGoatHamsterHorsePigRabbitSheepWater Buffalo
8000000G1CD3X
17DG1CD4XX
209MD26AG2aCD209XX
25-2AG1CD8X
25-2C (D422)MPredicted specificity CD45X
73/6.9.1G3CD8αX
74-11-10Gb2MHC IX
74-12-4G2bCD4X
74-22-15G1CD172a (SWC3)X
74-22-15AG2bCD172a (SWC3)X
74-9-3A1MCD45X
76-2-11G2aCD8αX
76-7-4G2aB cell and thymocytesX
7C2BG2aCD8αXXXXX
86DG1TCR1-N6 γ chanXX
86D1G1TCR1-N7 cluster, γ chain specific?X
8E6-2b3cG2bCD3X
8E6-8C8G2aCD3X
AC306BG1Granulocyte monocyteX
AV114AMThrombocytesX
AV129AMPan leukocyteX
AV14AMPan leukocyteX
AV18AMPan leukocyteX
AV191AMLate BX
AV213AG2aCD8X
AV243AG2aGranulocyte monocyteX
AV261CG3PanTX
AV309AG1CD4X
AV319AMCD8X
AV36AMPan leukocyteX
AV43AG3Pan leukocyteX
AV47AsIgMsIgMX
AV64AG1MHC IIX
AV66DG3CD4X
AV66DG3CD4X
AV67AG1αβ TX
AV92AMCD4X
B18AG1orG3CD9XX
B29AG2aCD5XX
B5CG2bMHC IX
B7AMWC1+ γδ T cell N1 epitopeXX
B7A1MWC1-N1XXXXX
BAG25AMWC1+ γδ T cell N28 epitopeX
BAG2BMWC1+ γδ T cell N27 epitopeX
BAG40AG3CD44XXXXXXXXX
BAG40AM- G3CD44XM
BAGB20AG1CD45 predictedX
BAGB45AG1CD5X
BAQ111AMCD8XXX
BAQ125AG2bPlateletsX
BAQ128AG1WC1+ γδ T cellX
BAQ151AG1CD11cX
BAQ153AMCD11cXXXXX
BAQ155AG1B cellsXX
BAQ159AG1WC1+ γδ T cell N4 subsetXX
BAQ15AMCD21XX
BAQ30AG1CD18XXXXXXXXXXXX
BAQ44AMB cellsXXXX
BAQ4AG1WC1-N2XXXXX
BAQ56AG1PlateletsX
BAQ83AG2bCD6XX
BAQ89AG1WC1-N4XXXXX
BAQ91AG1CD6XXX
BAQ92AG1CD62LXXX
BAQ95AG1CD2XXXX
BAT31AG1CD44XXXXXX
BAT72AG1CD8βX
BAT82AG1CD8βXXXX
BIBMab and gd T cellsX
BIG312D3G1IgAX
BIG501EG1λ light chainXXXXX
BIG715AG1IgG1XXXX
BIG73AG1sIgMXXX
Bo-IL-22G1IL-22XX
CACT105AG1CD5X
CACT108AG2aCD25XX
CACT114AG2bCD26X
CACT116AG1CD25XXXXX
CACT130AG3CD8αX
CACT138AG1CD4XXX
CACT152AMACT31X
CACT153AMACT37XX
CACT180AG1ACT34XXX
CACT191AMACT32X
CACT195AMACT27X
CACT200AG1ACT1XX
CACT200AG1SLAMF9X
CACT206AG2aACT1XX
CACT206AG2aSLAMF9X
CACT216AMCD50 - ACT28XXX
CACT21AG1WC1+ γδ T cell N31 epitopeX
CACT225AG1ACT29X
CACT22BG1TCR1-N7 γ chain specific?X
CACT243AMACT38X
CACT26AG1ACT2XX
CACT26AG2bCD26X
CACT282AMACT35X
CACT31ACD2MX
CACT61AMTCR1 δ chain specificX
CACT7AMACT1X
CACT80CG1CD8αXXXXX
CACT83BMCD4X
CACT83BMCD4X
CACTB21AG1WC1+ γδ T cell N29X
CACTB31AG2bWC1+ γδ T cell N30X
CACTB32AG1WC1-N3XXXX
CACTB51AG2aCD45X
CACTB6AMTCR1-N6 γ chain specific?XXXX
CACTB7AG1WC1+ γδ T cell N3epitopeXXX
CACTB81AG1TCR1-N7 γ chain specific?X
CADO13AMNeutrophilsX
CADO18AG1Pan leukocyteX
CADO19AG1CD45 predictedX
CADO21AG2bCD47 predictedX
CADO46AG1CD8X
CADO48AG1NeutrophilsX
CADO6AG1X
CAM36AG1CD14 LPS receptor (monocytes, variable on granulocytes in different species)XXXXXXXXXX
CAM66AMCD14 LPS receptor (monocytes, variable on granulocytes in different species)XXXXXX
CAPP2AG1CD41XXXXX
CAT30AG1CD4X
CAT82AG1MHC IIXX
CF26AG1Pan lymphocyteX
CF54AG1Pan T1X
CF74AG1Pan T2X
CF77AG1Pan lymphocytes and monocytesX
CF7AG1T subX
CH138AMGranulocytesXXX
CL2AG1CD41 PlateletsXXX
CL35AG1NeutrophilX
CT1.572 (T572)G2aCD5X
CT3.357 (T357)MCD8βX
CTOKT8G2aCD8X
DH13AMCD5X
DH16AMCD45RBXXXX
DH24AMCD90 - granulocytesXX
DH29AMCD4X
DH2AMCD90X
DH3BG1CD5X
DH59BG1CD172aXXXXXXXXX
DLL132AMCD21X
DLL20AMB and granulocytesX
DLL46AG1X
DLL51AG1BX
DLL76AG1BX
DOL10IL10XX
Do-TNF-αG1TNF-αXXX
DU1-29G1CD62LXX
E38AG1CD45R0 predictedX
EC1.1G1CD335X
ETC142B1AG2aCD8αX
ETC142B1AG2aCD8αX
F46AG1B cellXXX
F72AG1Granulocytes, monocytes, BX
FOX20AG2bFoxP3X
FOX5AG1Foxp3XX
FW3-218G2bCD49dXXXX
FW4-101G1CD29XXXXX
GB110AMACT16XX
GB112AG1CD25XXX
GB21AG2bTCR1-N24 δ chain specificXXX
GB25AG1CD21XXXX
GB26AMB cellsXX
GB45AG1WC1-N26XXXX
GB50AG1Pan leukocyte, endothelial cellsX
GB53AG1Gr, mono/ lymph subX
GB54AG2aWC1+ γδ T cell N25 epitopeXXX
GB54AG2aWC1-N25X
GC1AG2aCD4XX
GC34AMLymphocytes, monocytesX
GC42AG1CD45R0XX
GC50AMCD4XXXXX
GC5AG1PlateletsX
GC6AMCD45RXXXX
GRAN2A1G1GranulysinX
GS23AG1NeutrophilsX
GS5AG1CD45RXXXX
H1AG2aMHC IX
H20AG1CD18X
H22AG2aCD44?XX
H34AG2bMHC IIX
H42AG2aMHC II XXXXXXXX
H58AG2aMHC IXXXXXXXXXXX
HAB1AG1CD4X
HAB2AG1Pan TX
HAB6B = HASA18AG2aPan lymphocyteX
HACT39AG1GranulocytesX
HAL16AG1MHC IIX
HAL17AG2aBX
HAL36AG2aCD4X
HASA18AMPan lymphocyteX
HASA25AG1CD45 PredictedX
HASA26BG1GranulocytesX
HASA7AG1BX
HAT13AG2bCD45 PredictedX
HAT19AG2aPan T = HAB2AX
HB19AG2aCD5X
HB32AG2aCD45R0 predictedX
HB61AG1CD4X
HB65AG2aCD4 subX
HB72AG2aCD45R0 predictedX
HB86AG1CD4 subX
HB88AG1CD2X
HT14AG1CD8βX
HT23AG1CD5X
HUH71AG1CD47XXX
HUH73AG1CD11aXXXXXXXX
HUH82AG2aCD18XXXXXXX
I LA158AG1CD40X
IL11AG2aCD4XX
IL-17AG1Bo-IL-17AXX
ILA114AG1CD205X
ILA116AG3CD45R0XXXXX
ILA-11AG2aCD4XX
ILA158AG1CD40XX
ILA159G1CD80XX
ILA190AG1CD86XX
ILA29G1WC1+ γδ T cellXX
ILA29AG1WC1X
ILA53AG2aCD205X
ILA77AMCD71XX
ISC16AMCD8X
ISC18AG2aCD45X
ISC27AG2aCD8X
ISC29EG1CD8X
ISC38AG1CD8X
ISC39AG1CD45X
ISC76AMCD45X
KTSN7AG1CD69XXX
LCT27AG1CD45RX
LCTB2AG3CD25XXXXX
LCTB32AMCD25XX
LCTB6AG1ACT9X
LH41AMBX
LH43AG1CD2/CD6 likeX
LH7AMB subX
LH9AMACT1X
LND37AG1MonocytesX
LND41AG1DC and a subset of innate lymphoid cellsX
LND68AG1MonocytesXXX
LT10AG2aCD2/CD6 likeX
LT12AG2aCD45 predictedX
LT1AG2aMHC IIX
LT36AG2bCD44XX
LT3AG1CD5 likeX
LT41AG2aCD44XX
LT48AG2aCD11aX
LT4AG2aCD5 likeX
LT5AG2aCD8X
LT78AMB subX
LT79AG3B subX
LT86AG2aCD9XX
LT97AG2bPan TX
MM10AG2bCD11bXX
MM12AG1CD11bXXXXX
MM1AG1CD3XXX
MM20AG1Granulocytes = CH138AXX
MM20AG1Neutrophils/monocytesX
MM61AG1CD14X
MRB102AMPan lymphocyteX
MRB107AG1B subX
MRB120AG1Granulocytes, basophils, monocytesX
MRB25AMBX
MRB61AG1T3X
MSA3G2aMHC II HLA DR orthologueX
MSA4G2aCD2X
MUC127AG2aTCR1 γ chainX
MUC2AG2aCD2XX
MUC2AG2aCD2XXXX
MUC76AG2aCD11aX
MUC93AG1CD59 need validationX
NK29AG1CD26XX
NK29AG1NK Cluster 2 activation moleculeX
NK47AG2aCD26X
NK47AG2aNK Cluster 2X
NK64AG1Gp96XX
NK64AG1NK Cluster 1X
OKT8G2aCD8X
PG104AMCD8+ CD4 sub, γδ small subX
PG106AMPan lymphocyteX
PG114AG1CD5X
PG124AG1CD27 (SWC2)X
PG145AMsIgMX
PG164AG2aCD8βX
PG167AG1CD45RAX
PG168AG3CD2X
PG68AG1GranulocytesX
PG74CMSubsets γδ CD4 CD8 T cellsX
PG77AMCD45RAX
PG83AG3SWC4X
PG89AG1Pan lymphocyteX
PG90AG1CD6X
PG92AMSWC5X
PG94AMSubset SWC6+ γδ T cellsX
PG96AG1CD45RAX
PG97AMCD45RAX
PGB78AG2aCD45RAX
PGBL22AG1TCR1 δ chain specificX
PGBL23AG1CD2X
PGBL24AMSubset γδ T cellsX
PGBL25AG1CD25X
PGBL31AG1Subset γδ T cellsX
PIG45AG2bsIgMX
PIG45A2G2bIgMXXX
PT14AG2aTCR1 γ chainX
PT36AG1CD8αX
PT79AG2aTCR1 γ chaintX
PT81BG2bCD8αX
PT85AG2aMHC IXXXXXXXX
PT90AG2aCD4X
RACT19AMCD4 CD8 SUB CD28?X
RACT20AG1Basophils and sub CD4 CD8X
RACT38AG1Pan leukocyteX
RACT43AMGranulocytesX
RACT44AMGranulocytesX
RACT48AG2aCD11aX
RACT48AG2aCD18X
RH1AG3CD9XXXXX
RIF60AG1IFN-γXX
RT18AMCD11bX
RT19AMB subX
RT22AMT2 = RTH21AX
RTH161AG1CD18X
RTH186AG1Pan lymphocyteX
RTH192AG1CD5X
RTH1AG1CD4X
RTH21AG1T2X
RTH26AG2aT4X
RTH2AG1T1X
RTH32AMCD58X
RTH33AG1CD58X
ST1AIgG2aCD5X
ST8MCD8XX
TE1AMCD28XX
TH14BG2aMHC II HLA-DRXXXXXXXXXXX
TH16AG2aMHC IIX
TH17AMCD47XXXXXX
TH18AG3Pan lymphocyteX
TH21AG2bMHC IIX
TH22AG2aMHC IIX
TH81AG2aMHC II HLA-DQXXXXXXXXXXX
TH97AG2aCD1bXX
W6/32G2aMHC IX

About us

In the mid-70s, a group of investigators demonstrated in mice that it is possible to immortalize B lymphocytes producing single monospecific antibodies (mAbs) by fusing B lymphocytes to tissue culture adapted myeloma (malignant form of an antibody producing cell) cells. The hybrid cells (hybridomas) were stable and could be maintained in culture indefinitely or preserved in liquid nitrogen for later use. These findings represented a major breakthrough in the way antibody reagents could be developed for basic and biomedical research. Mice could be immunized with antigens of interest and then used as a source of B lymphocytes to produce mAbs of known specificity. The spleen was shown to be the best source of B lymphocytes for making hybridomas. Hybridomas producing the desired mAbs could be identified by examining culture medium from primary cultures of fused cells. In subsequent investigations, myeloma fusion partners were developed that could only grow in selective growth medium if fused to a B lymphocyte, eliminating the problem of distinguishing hybridomas from cells that had not fused with a B lymphocyte. Myeloma fusion partners were later identified that could no longer produce their own antibody but could produce antibody derived from the B lymphocyte. These advances simplified and improved the methodology for producing mAbs.

Research universities, research institutes and industry established core facilities to exploit mAb technology to develop mAbs for use as analytical tools in the biological and biomedical sciences, in the characterization of the immune system, study the mechanisms by which pathogens cause disease, develop improved diagnostic assays, and identify antigens from pathogens that can be used in subunit vaccines. Because of our research needs, we started developing mAbs for use in food and companion animal research and diagnostic medicine in 1979. To encourage other investigators to use mAb technology, we sponsored the first international symposium and workshop ‘Impact of Monoclonal Antibody Technology on Animal and Plant Agricultural Research’ in June of 1982. We also participated in a workshop sponsored by the National Research Council of the National Academy of Science on ‘Priorities in Biotechnology Research for International Development held in July of 1982, a symposium sponsored by the USDA ‘Hybridoma Technology in Agricultural and Veterinary Research’ held in Oct. of 1983 and an international conference sponsored by the International Laboratory for Research on Animal Diseases ‘The Ruminant Immune System In Health and Disease’ held in Kenya Africa in September 1983. In 1984, we co-sponsored a meeting with Australia ‘Characterization of the Bovine Immune System and the Genes Regulating Expression of Immunity with Particular Reference to their Role in Disease Resistance’ held in Honolulu, Hawaii. During this period of time, we developed some of the first sets of mAbs for use in the study of the immune system in food and companion animals. We also participated in all the international workshops to characterize the first sets of mAbs.

Goals

The Washington State University Monoclonal Antibody Center was established in 1982 with the following goals:

  1. Provide a central facility for the production of mAbs for investigators that do not have the facilities or expertise to produce mAbs for their research.
  2. Develop and use mAbs to study the mechanisms regulating the immune response to pathogens and candidate subunit vaccines in veterinary species.
  3. Provide a source of mAbs for the research community for use in food and companion animal research.
  4. Provide graduate and professional training in the use of mAb technology in research and the development of diagnostic reagents.
  5. Provide graduate and professional training in the use of mAbs in immunology and flow cytometry.
  6. Collaborate with investigators requiring expertise and resources available through the center to conduct studies in immunology.
  7. Aid in the development of clinical flow cytometry diagnostic services in veterinary medicine.